Latest papers

Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice.

Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor.

Potential molecular targets in chemopreventative action of celecoxib: a proteomics analysis of J774.A1 macrophage-like cell line.

The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.

More on crizotinib.

More on crizotinib.

More on crizotinib.

Crizotinib in anaplastic large-cell lymphoma.

Current treatment options for primary immune thrombocytopenia.

JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.

[Bringing evidence to practice: obstacles and barriers].

Inhibition of HERG potassium channels by celecoxib and its mechanism.

Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome.

The CB₁ receptor antagonist SR141716A reverses adult male mice overweight and metabolic alterations induced by early stress.

Celecoxib can induce vascular endothelial growth factor expression and tumor angiogenesis.

AZ960, a novel Jak2 inhibitor, induces growth arrest and apoptosis in adult T-cell leukemia cells.

A phase II trial of weekly i.v. KW-2170 in advanced castrate-resistant prostate cancer.

A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration.

Role of leukotriene B4 in celecoxib-mediated anticancer effect

Antitumor activity of new hydridotris(pyrazolyl)borate ruthenium(II) complexes containing the phosphanes PTA and 1-CH3-PTA.